The in vivo release of human platelet factor 4 by heparin.
Intravenous and subcutaneous injection of heparin or the heparin analogue SSHA into normal volunteers induced release of platelet factor 4 (PF4) but not beta-thromboglobulin (beta-TG). At low heparin doses the amount of PF4 released was related to the plasma heparin concentration achieved. The rise in plasma PF4 was coincident with, and appeared to be a response to, the increase in plasma heparin concentration rather than to the absolute heparin level. After the primary response, the system became refractory to further challenge by the same heparin dose; the full initial magnitude of the response was not regained until 144 h. after heparin was first injected. The maximum amount of PF4 released corresponded to only about 5% of that potentially available from platelets. Moreover, heparin did not stimulate PF4 release from whole blood in vitro. We have demonstrated the presence of PF4 on the vascular endothelium, and suggest that this is the immediate source of the PF4 released by heparin, though it is probably initially derived from platelets. The effect of such binding on the antithrombotic potential of the endothelial surface is discussed.
D000818:Animals; D001779:Blood Coagulation Factors / Q000032:analysis*; D003594:Cytoplasmic Granules / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004727:Endothelium / Q000032:analysis; D006493:Heparin; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D010978:Platelet Factor 4 / Q000032:analysis*; D011817:Rabbits; D013923:Thromboembolism / Q000175:diagnosis; D014471:Umbilical Veins / Q000032:analysis; D001620:beta-Thromboglobulin / Q000032:analysis
D001779:Blood Coagulation Factors; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D006493:Heparin